ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SBFM vs PRFX // ALTMAN Z-SCORE & DEBT/EQUITY

Sunshine Biopharma Inc. (NASDAQ) VS. PRF Technologies Ltd. (NASDAQ) • 15-METRIC TALLY: SBFM 5 — PRFX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SBFM VS. PRFX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SBFM PRFX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 33.80% -30.00% +63.80 SBFM /gross-margins <GO>
Return on Invested Capital (ROIC) -21.40% -35.00% +13.60 SBFM /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -17.20% -60.00% +42.80 SBFM /operating-margins <GO>
Net Profit Margin -16.50% -60.00% +43.50 SBFM /net-margins <GO>
Revenue Growth (YoY) 4.10% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 SBFM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 29.9 40.1 -10.20 PRFX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.5M $2.6M -$91.0K PRFX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SBFM REV PRFX REV SBFM GROSS % PRFX GROSS % SBFM FCF PRFX FCF
FY 2025 $36.3M $17.0K 33.8% -50.0% -$5.5M -$4.0M
FY 2024 $34.9M $0 30.6% — -$14.2M -$12.6M
FY 2023 $24.1M $0 — — -$8.8M -$6.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SBFM // BETA —
PRFX // BETA —